Bristol-Myers Phase 3 Opdivo Study Misses a Main Endpoint
05 September 2019 - 2:06PM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) on Thursday said a phase 3 study
evaluating the addition of its cancer drug Opdivo to the current
standard of care to treat a form of the aggressive tumor
glioblastoma multiforme didn't meet the primary endpoint of
progression-free survival.
The New York biopharmaceutical company, which remains blinded to
the data, said the study's data monitoring committee recommended
the trial continue as planned to allow the other primary endpoint,
overall survival, to mature.
Bristol-Myers said the study involves the addition of Opdivo to
the chemotherapy drug temozolomide and radiation therapy in
patients with newly diagnosed glioblastoma multiforme that is
O6-methylguanine-DNA methyltransferase-methylated.
Glioblastoma multiforme is the most common and most aggressive
type of primary malignant tumor of the central nervous system.
Opdivo, which harnesses the body's immune system to fight
cancer, has been approved for use in several types of cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 05, 2019 07:51 ET (11:51 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024